Biliary stent combined with or without iodine 125 seed strands implantation for the treatment of Cholangiocarcinoma with malignant obstructive jaundice: a prospective, non-randomized, controlled clinical study

Technical development and therapeutic effect of iodine-125 seeds in the treatment of malignant obstructive jaundice

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100055040

Enrollment

Unknown

Registered

2021-12-31

Start date

2018-01-01

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatobiliary malignancy

Interventions

experimental group:PTCD+ biliary stent + iodine-125 seeds implantation

control group:PTCD+ biliary stent

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged >=18 and = 60 x 10^9/L, hemoglobin (HB) >= 80g/L, prothrombin time (PT) prolonged < 4s; 5.PS score 0 ~ 1.

Exclusion criteria

Exclusion criteria: 1.Patients with major organ diseases, such as severe dysfunction of heart, lung, liver and kidney, are expected to have difficulty tolerating interventional surgery; 2.Multiple intrahepatic metastases or diffuse intrahepatic bile duct stenosis, and biliary stent cannot pass through; 3.With extensive systemic metastasis, the expected survival was < 3 months.

Design outcomes

Primary

Measure	Time frame
Serum total bilirubin;Biliary tract patency rate;AE rate;	—

Countries

China

Contacts

Public ContactLUO JUN

The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Institute of Basic Medicine and Cancer(IBMC),Chinese Academy of Sciences

bjy0927@163.com+8613186976014

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026